Bistra Kirova

Bistra Kirova

AstraZeneca, Sweden - Södertälje / Sweden
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 5674305
-
person_outline Bistra Kirova's MOST POPULAR ARTICLES
1-) Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with …R Baird, M Oliveira, EMC Gil, MR Patel, B Bermejo de las Heras, ...Cancer research 81 (4_Supplement), PS11-05-PS11-05, 2021342021
2-) Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the …M Oliveira, D Pominchuck, Z Nowecki, E Hamilton, Y Kulyaba, ...Cancer Research 83 (5_Supplement), GS3-02-GS3-02, 2023242023
3-) Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a …M Oliveira, D Pominchuk, Z Nowecki, E Hamilton, Y Kulyaba, ...The Lancet Oncology 25 (11), 1424-1439, 202412024
4-) RANDOMIZED OPEN-LABEL STUDY TO ASSESS RELATIVE BIO-AVAILABILITY OF DIFFERENT ORAL FORMULATIONS, THE EFFECT OF FOOD ON ABSORPTION AND ABSOLUTE BIOAVAILABILITY OF AZD9833 …A Sykes, H Engman, N Taylor, T Brier, R Maudsley, B Kirova, ...CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S51-S51, 20222022